Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

Biocon launches Liraglutide, a GLP-1 peptide, in the UK for diabetes and obesity management. This marks the first generic ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biocon has announced the launch of its GLP-1 peptide Liraglutide for diabetes and obesity in the United Kingdom (U.K.).

After the Indian market ended the monthly expiry session on a sour tone, the early Gift Nifty trend on Friday indicated to a ...

Kotak Institutional Equities suggests that high US tariffs on pharmaceuticals are unlikely. They maintain an optimistic ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., ...

The Nifty Pharma index closed on a negative note on Thursday. Shares of Sun Pharmaceutical Industries Ltd.(up 2.11 per cent), ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...